Article
First HDAC Inhibitor, Developed by Novartis, Approved for Multiple Myeloma
Study results showed participants receiving Farydak with bortezomib and dexamethasone saw a progression-free survival for about 10.6 months,compared to 5.8 months in participants treated with bortezomib and dexamethasone alone.
The FDA approved Farydak (panobinostat) for the treatment of patients with multiple myeloma.
Multiple myeloma is a form of blood cancer that arises from plasma cells, a type of white blood cell, found in bone marrow. According to the National Cancer Institute, approximately 21,700 Americans are diagnosed with multiple myeloma and 10,710 die from the disease annually.
Primarily affecting older adults, multiple myeloma causes plasma cells to rapidly multiply and crowd out other healthy blood cells from the bone marrow. When the bone marrow has too many plasma cells, the cells may move to other parts of the body, which can weaken the body’s immune system, lead to anemia and cause other bone and kidney problems.
Read the complete FDA press release: http://1.usa.gov/1w3YB9A
